Cable Hill Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Cable Hill Partners’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-125	Closed	-$12K	–	1016
2017 Q2	$12K	Buy	+125	New	+$7.65K	0.01%	374

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cable Hill Partners's CLVS Position: Q3 2017 in Review

Cable Hill Partners sold out of Clovis Oncology, Inc. (CLVS) in Q3 2017, closing a stake of 125 shares — an estimated $12K sold.

Cable Hill Partners first reported a position in CLVS in Q2 2017 and held it in 1 quarter. The position peaked at $12K in Q2 2017. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

Cable Hill Partners reported no remaining Clovis Oncology, Inc. position as of Q3 2017 after selling out during the quarter.
Cable Hill Partners sold 125 Clovis Oncology, Inc. shares in Q3 2017, an estimated $12K.
Cable Hill Partners first reported a position in Clovis Oncology, Inc. in Q2 2017 and held it in 1 quarter.
Cable Hill Partners's Clovis Oncology, Inc. position peaked at $12K in Q2 2017.
255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Cable Hill Partners's 13F filing for Q3 2017, filed 27 Oct 2017.